Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 9/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12380084 | 1.00 | RORC (0.43) | RORCKEAP1NFE2L2TP53MAPT | |
| SCHEMBL12380777 | 1.00 | RORC (0.43) | RORCKEAP1NFE2L2TP53MAPT | |
| SCHEMBL12380837 | 0.93 | RORC (0.45) | RORCKEAP1NFE2L2HPGDMAPK14 | |
| SCHEMBL12380778 | 0.93 | RORC (0.45) | RORCKEAP1NFE2L2HPGDMAPK14 | |
| SCHEMBL12380834 | 0.93 | RORC (0.45) | RORCKEAP1NFE2L2HPGDMAPK14 | |
| SCHEMBL12380391 | 0.91 | RORC (0.43) | RORCKEAP1NFE2L2TP53MAPT | |
| SCHEMBL12380073 | 0.91 | RORC (0.43) | RORCKEAP1NFE2L2TP53MAPT | |
| SCHEMBL12380811 | 0.91 | RORC (0.43) | RORCKEAP1NFE2L2TP53MAPT | |
| SCHEMBL1645971 | 0.91 | NR1H4 (0.41) | KEAP1NFE2L2MEN1KMT2AHTT | |
| SCHEMBL12361938 | 0.91 | NR1H4 (0.41) | KEAP1NFE2L2MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | RORC 4132/4885KEAP1 1130/4885NFE2L2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.